Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT07652138
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-07-30Est. Completion: 2027-01-01
Enrollment target: 18 participants Locations- The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Other microbiome trials you might be interested in
De Novo Multiple MyelomaAnitocabtagene Autoleucel
The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adul…
Badalona, SpainEst. completion Mar 31, 2028
Multiple Myloma
• To Evaluate the role of uromodulin level in early diagnosis of cast nephropathy and to detect its prognostic value in …
Asyut, EgyptEst. completion Mar 25, 2027